|
Pediatric Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
Conclusions lncRNA HCP5 could serve as a ceRNA sponging miR-17-5p and miR-27a/b to regulate the pathogenesis of childhood obesity via NLK and RRAS2 in the MAPK signaling pathway.
|
31622249 |
2019 |
|
Carcinogenesis
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
However, little information exists on the function of RRAS2 in tumorigenesis of osteosarcoma.
|
31517733 |
2019 |
|
Malignant transformation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Aberrant function of RRAS2 drives malignant transformation in a various of cancers.
|
31517733 |
2019 |
|
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RNA interference decreased the gene and protein expression of RRAS2, reduced in-vitro the proliferation and migration of osteosarcoma cells, and suppressed the activation of the MEK/ERK signaling pathway.
|
31517733 |
2019 |
|
Osteosarcoma of bone
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RNA interference decreased the gene and protein expression of RRAS2, reduced in-vitro the proliferation and migration of osteosarcoma cells, and suppressed the activation of the MEK/ERK signaling pathway.
|
31517733 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
RNA interference decreased the gene and protein expression of RRAS2, reduced in-vitro the proliferation and migration of osteosarcoma cells, and suppressed the activation of the MEK/ERK signaling pathway.
|
31517733 |
2019 |
|
Noonan Syndrome
|
0.620 |
Biomarker
|
disease |
CLINGEN |
Here, we report four de novo RRAS2 variants in three individuals with NS.
|
31130285 |
2019 |
|
Noonan Syndrome
|
0.620 |
GeneticVariation
|
disease |
BEFREE |
Here, we report four de novo RRAS2 variants in three individuals with NS.
|
31130285 |
2019 |
|
Noonan Syndrome
|
0.620 |
GermlineCausalMutation
|
disease |
ORPHANET |
Here, we report four de novo RRAS2 variants in three individuals with NS.
|
31130285 |
2019 |
|
Macrocephaly
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Larvae overexpressing c.70_78dup (p.Gly24_Gly26dup) or c.216A>T (p.Gln72His) variants, but not wild-type RRAS2 RNAs, showed craniofacial defects and macrocephaly.
|
31130285 |
2019 |
|
Noonan Syndrome
|
0.620 |
Biomarker
|
disease |
CLINGEN |
We show that the NS-causing RRAS2 variants affect highly conserved residues localized around the nucleotide binding pocket of the GTPase and are predicted to variably affect diverse aspects of RRAS2 biochemical behavior, including nucleotide binding, GTP hydrolysis, and interaction with effectors.
|
31130282 |
2019 |
|
Noonan Syndrome
|
0.620 |
GeneticVariation
|
disease |
BEFREE |
We show that the NS-causing RRAS2 variants affect highly conserved residues localized around the nucleotide binding pocket of the GTPase and are predicted to variably affect diverse aspects of RRAS2 biochemical behavior, including nucleotide binding, GTP hydrolysis, and interaction with effectors.
|
31130282 |
2019 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Waist-Hip Ratio
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Vitamin D3 measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Low-Frequency Synonymous Coding Variation in CYP2R1 Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis.
|
28757204 |
2017 |
|
Vitamin D measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Low-Frequency Synonymous Coding Variation in CYP2R1 Has Large Effects on Vitamin D Levels and Risk of Multiple Sclerosis.
|
28757204 |
2017 |
|
Juvenile Myelomonocytic Leukemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of juvenile myelomonocytic leukemia.
|
26457647 |
2015 |
|
Noonan Syndrome
|
0.620 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis.
|
24705357 |
2014 |
|
Malignant neoplasm of skin
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Studying the interaction between miR-23b and its putative skin-relevant targets using a Luciferase reporter assay revealed that RRAS2 (related RAS viral oncogene homolog 2), which is strongly expressed in highly aggressive malignant skin cancer, to be a direct target of miR-23b.
|
24391759 |
2013 |
|
Carcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Significantly, both wild type and mutated RRAS2 (also known as TC21) are overexpressed in human carcinomas of the oral cavity, esophagus, stomach, skin and breast, as well as in lymphomas.
|
24148564 |
2013 |
|
Lymphoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Significantly, both wild type and mutated RRAS2 (also known as TC21) are overexpressed in human carcinomas of the oral cavity, esophagus, stomach, skin and breast, as well as in lymphomas.
|
24148564 |
2013 |
|
Esophageal Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Results suggest that TC21 mediates its effects via the PI3K-Akt pathway, NF-κB and cyclin D1, and enhances chemoresistance in esophageal cancer cells.
|
22919244 |
2012 |
|
Esophageal carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Results suggest that TC21 mediates its effects via the PI3K-Akt pathway, NF-κB and cyclin D1, and enhances chemoresistance in esophageal cancer cells.
|
22919244 |
2012 |
|
Squamous cell carcinoma of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, we evaluated the potential of TC21 as a putative target for sensitizing ESCC cells to the chemotherapeutic agent cisplatin.
|
22919244 |
2012 |
|
Malignant neoplasm of esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Results suggest that TC21 mediates its effects via the PI3K-Akt pathway, NF-κB and cyclin D1, and enhances chemoresistance in esophageal cancer cells.
|
22919244 |
2012 |